352 related articles for article (PubMed ID: 21677673)
1. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
[TBL] [Abstract][Full Text] [Related]
2. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
3. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
Bianchi S; Bigazzi R; Campese VM
Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
5. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
6. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis.
Takahashi S; Katada J; Daida H; Kitamura F; Yokoyama K
J Hum Hypertens; 2016 Sep; 30(9):534-42. PubMed ID: 26674759
[TBL] [Abstract][Full Text] [Related]
7. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
[TBL] [Abstract][Full Text] [Related]
8. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
[TBL] [Abstract][Full Text] [Related]
9. Hyperkalemia in both surgically and medically treated patients with primary aldosteronism.
Wada N; Shibayama Y; Umakoshi H; Ichijo T; Fujii Y; Kamemura K; Kai T; Sakamoto R; Ogo A; Matsuda Y; Fukuoka T; Tsuiki M; Suzuki T; Naruse M
J Hum Hypertens; 2017 Oct; 31(10):627-632. PubMed ID: 28540931
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
[TBL] [Abstract][Full Text] [Related]
12. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
Gwoo S; Kim YN; Shin HS; Jung YS; Rim H
Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
[TBL] [Abstract][Full Text] [Related]
13. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
Sica DA
Methodist Debakey Cardiovasc J; 2015; 11(4):235-9. PubMed ID: 27057293
[TBL] [Abstract][Full Text] [Related]
15. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
[TBL] [Abstract][Full Text] [Related]
16. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
Abolghasmi R; Taziki O
Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):75-8. PubMed ID: 21196617
[TBL] [Abstract][Full Text] [Related]
18. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
Edwards NC; Steeds RP; Chue CD; Stewart PM; Ferro CJ; Townend JN
Br J Clin Pharmacol; 2012 Mar; 73(3):447-54. PubMed ID: 21950312
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.
Mavrakanas TA; Giannetti N; Sapir-Pichhadze R; Alam A
Cardiorenal Med; 2020; 10(1):32-41. PubMed ID: 31665724
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis.
Sinnott SJ; Tomlinson LA; Root AA; Mathur R; Mansfield KE; Smeeth L; Douglas IJ
Eur J Prev Cardiol; 2017 Feb; 24(3):228-238. PubMed ID: 27856806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]